Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of ductal carcinoma in situ and the workup and locoregional management of early stage invasive breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org.

Related collections

Most cited references 207

Record: found
Abstract: found
Article: not found

Is Open Access

Cancer statistics, 2022

Rebecca Siegel, Kimberly D Miller, Hannah Fuchs … (2022)

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes. Incidence data (through 2018) were collected by the Surveillance, Epidemiology, and End Results program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2019) were collected by the National Center for Health Statistics. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. Incidence during 2014 through 2018 continued a slow increase for female breast cancer (by 0.5% annually) and remained stable for prostate cancer, despite a 4% to 6% annual increase for advanced disease since 2011. Consequently, the proportion of prostate cancer diagnosed at a distant stage increased from 3.9% to 8.2% over the past decade. In contrast, lung cancer incidence continued to decline steeply for advanced disease while rates for localized-stage increased suddenly by 4.5% annually, contributing to gains both in the proportion of localized-stage diagnoses (from 17% in 2004 to 28% in 2018) and 3-year relative survival (from 21% to 31%). Mortality patterns reflect incidence trends, with declines accelerating for lung cancer, slowing for breast cancer, and stabilizing for prostate cancer. In summary, progress has stagnated for breast and prostate cancers but strengthened for lung cancer, coinciding with changes in medical practice related to cancer screening and/or treatment. More targeted cancer control interventions and investment in improved early detection and treatment would facilitate reductions in cancer mortality.

0 comments Cited 5553 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer

Bernard Fisher, Stewart Anderson, John Bryant … (2002)

New England Journal of Medicine, 347(16), 1233-1241

0 comments Cited 1176 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

Norikazu Masuda, Soo-Jung Lee, Byeong-Woo Park … (2017)

Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer have poor prognoses. The benefit of adjuvant chemotherapy in these patients remains unclear.

0 comments Cited 585 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Title: Journal of the National Comprehensive Cancer Network

Publisher: Harborside Press, LLC

ISSN (Print): 1540-1405

ISSN (Electronic): 1540-1413

Publication date Created: June 2022

Publication date (Print): June 2022

Volume: 20

Issue: 6

Pages: 691-722

Affiliations

[1 ]1Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

[2 ]2Yale Cancer Center/Smilow Cancer Hospital;

[3 ]3Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

[4 ]4Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

[5 ]5The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

[6 ]6Stanford Cancer Institute;

[7 ]7University of Wisconsin Carbone Cancer Center;

[8 ]8Dana-Farber/Brigham and Women’s Cancer Center;

[9 ]9UC Davis Comprehensive Cancer Center;

[10 ]10Memorial Sloan Kettering Cancer Center;

[11 ]11University of Colorado Cancer Center;

[12 ]12The University of Texas MD Anderson Cancer Center;

[13 ]13Mayo Clinic Cancer Center;

[14 ]14Fox Chase Cancer Center;

[15 ]15UCLA Jonsson Comprehensive Cancer Center;

[16 ]16Massachusetts General Hospital Cancer Center;

[17 ]17Abramson Cancer Center at the University of Pennsylvania;

[18 ]18Fred Hutchinson Cancer Research Center/University of Washington;

[19 ]19Fred & Pamela Buffet Cancer Center;

[20 ]20UT Southwestern Simmons Comprehensive Cancer Center;

[21 ]21City of Hope National Medical Center;

[22 ]22University of Michigan Rogel Cancer Center;

[23 ]23Duke Cancer Institute;

[24 ]24UCSF Helen Diller Family Comprehensive Cancer Center;

[25 ]25UC San Diego Moores Cancer Center;

[26 ]26The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

[27 ]27Research Advocacy Network;

[28 ]28Moffitt Cancer Center;

[29 ]29O'Neal Comprehensive Cancer Center at UAB;

[30 ]30Huntsman Cancer Institute at the University of Utah;

[31 ]31Roswell Park Comprehensive Cancer Center; and

[32 ]32National Comprehensive Cancer Network.

Article

DOI: 10.6004/jnccn.2022.0030

PubMed ID: 35714673

SO-VID: 0703ebce-14b5-4a9d-9941-5d852adb7e04

History

Data availability:

Comments

Comment on this article

scite_

Cited by 196

See all cited by

Most referenced authors 3,757

See all reference authors

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Read this article at

Abstract

Related collections

Karger: Oncology

Most cited references 207

Cancer statistics, 2022

Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 910

Cited by 196

Most referenced authors 3,757